Skandinaviska Enskilda Banken AB publ Sells 37,549 Shares of Exact Sciences Corporation $EXAS

Skandinaviska Enskilda Banken AB publ decreased its stake in shares of Exact Sciences Corporation (NASDAQ:EXAS) by 10.2% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 332,180 shares of the medical research company’s stock after selling 37,549 shares during the quarter. Skandinaviska Enskilda Banken AB publ owned about 0.18% of Exact Sciences worth $17,646,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Y Intercept Hong Kong Ltd bought a new position in shares of Exact Sciences during the 2nd quarter worth about $3,716,000. Teacher Retirement System of Texas increased its position in Exact Sciences by 640.7% in the 2nd quarter. Teacher Retirement System of Texas now owns 200,397 shares of the medical research company’s stock valued at $10,649,000 after buying an additional 173,343 shares in the last quarter. Gagnon Securities LLC increased its position in Exact Sciences by 3.0% in the 2nd quarter. Gagnon Securities LLC now owns 278,789 shares of the medical research company’s stock valued at $14,815,000 after buying an additional 8,125 shares in the last quarter. Woodline Partners LP raised its stake in Exact Sciences by 62.0% during the 1st quarter. Woodline Partners LP now owns 537,863 shares of the medical research company’s stock worth $23,284,000 after buying an additional 205,875 shares during the period. Finally, Bank Pictet & Cie Europe AG boosted its holdings in Exact Sciences by 27.2% in the second quarter. Bank Pictet & Cie Europe AG now owns 163,204 shares of the medical research company’s stock worth $8,673,000 after acquiring an additional 34,914 shares in the last quarter. 88.82% of the stock is owned by institutional investors.

Insider Transactions at Exact Sciences

In other Exact Sciences news, EVP Brian Baranick sold 2,858 shares of Exact Sciences stock in a transaction dated Tuesday, November 4th. The shares were sold at an average price of $70.08, for a total value of $200,288.64. Following the sale, the executive vice president owned 22,368 shares of the company’s stock, valued at approximately $1,567,549.44. The trade was a 11.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Jacob A. Orville sold 5,000 shares of the business’s stock in a transaction dated Wednesday, November 19th. The shares were sold at an average price of $75.00, for a total transaction of $375,000.00. Following the completion of the transaction, the executive vice president owned 23,237 shares in the company, valued at approximately $1,742,775. The trade was a 17.71% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 9,858 shares of company stock worth $695,289 in the last ninety days. Company insiders own 1.20% of the company’s stock.

Exact Sciences Trading Down 0.1%

NASDAQ:EXAS opened at $101.35 on Friday. Exact Sciences Corporation has a 52 week low of $38.81 and a 52 week high of $101.87. The firm has a 50-day moving average price of $67.66 and a two-hundred day moving average price of $57.12. The company has a debt-to-equity ratio of 0.94, a quick ratio of 2.56 and a current ratio of 2.89. The firm has a market cap of $19.20 billion, a price-to-earnings ratio of -18.66, a price-to-earnings-growth ratio of 5.56 and a beta of 1.34.

Exact Sciences (NASDAQ:EXAS) last released its earnings results on Monday, November 3rd. The medical research company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.13 by $0.11. The company had revenue of $850.74 million during the quarter, compared to analyst estimates of $810.42 million. Exact Sciences had a negative return on equity of 1.75% and a negative net margin of 34.19%.Exact Sciences’s quarterly revenue was up 20.0% on a year-over-year basis. During the same period in the prior year, the company posted ($0.21) earnings per share. Exact Sciences has set its FY 2025 guidance at EPS. On average, equities analysts expect that Exact Sciences Corporation will post -0.58 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently commented on EXAS. Zacks Research upgraded Exact Sciences from a “hold” rating to a “strong-buy” rating in a report on Monday, October 6th. Benchmark downgraded shares of Exact Sciences from a “buy” rating to a “hold” rating in a research report on Monday. William Blair lowered shares of Exact Sciences from an “outperform” rating to a “market perform” rating in a research note on Thursday, November 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Exact Sciences in a research note on Wednesday, October 8th. Finally, TD Cowen cut shares of Exact Sciences from a “strong-buy” rating to a “hold” rating in a report on Monday, November 24th. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, eighteen have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Exact Sciences presently has a consensus rating of “Hold” and an average price target of $85.00.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.